ARV-825, a hetero-bifunctional proteolysis-targeting chimera (PROTAC), exerts a more effective inhibition of c-MYC levels and downstream signaling than small-molecule BRD4 inhibitors in Burkitt’s lymphoma cell lines, resulting in a significant decrease in cell proliferation and an increase in apoptosis (Fig. 3) [70, 71]. Here, BRD4 is linked to Burkitt lymphoma.